Our expert for hiPSC-derived cardiac cells, as well as cell-based assays & services for drug safety and efficacy screenings
The use of Cor.4U® and Pluricyte® Cardiomyocytes in combination with the CardioExcyte 96 system has been optimized. This combination enables detailed detection of potential cardioactive and proarrhythmic effects of test compounds on the contractility and electrophysiology of cardiomyocytes in a 96-well plate format.
Cor.4U® and Pluricyte® Cardiomyocytes in combination with the CardioExcyte 96 system provide a highly relevant in vitro assay platform to study the cardiac safety profile of compounds during drug development.
You can find a step-by-step description on how to combine Cor.4U® Cardiomyocytes with the CardioExcyte 96 system in our User Guide.
Case studies were performed to assess the effects of cardioactive compounds on the electrophysiology (i.e. extracellular field potential, EFP) and impedance of Cor.4U® and Pluricyte® Cardiomyocytes using the CardioExcyte 96 system. Both hiPSC-derived cardiomyocytes showed expected pharmacological responses in a reproducible manner, which could be readily detected with the CardioExcyte 96 system.
Below, an example is shown of the effect of the reference compound, nifedipine, in Pluricyte® Cardiomyocytes.
Pharmacological response of Pluricyte® Cardiomyocytes to nifedipine
As expected, the L-type calcium channel blocker, nifedipine, induced a concentration-dependent decrease in impedance peak-amplitude (left) and in field potential duration (right) in Pluricyte® Cardiomyocytes.
Download the complete application notes here: